Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing

Key Takeaways

• FDA approves Restylane Contour for temple hollowing.
• Clinical trial shows 91% response at three months.
• Results last up to 18 months with high satisfaction.
• Dual‑depth injection offers precise, customizable treatment.
• Growing demand due to medication‑induced weight loss.

Pulse Analysis

The FDA’s endorsement of Restylane Contour for temple hollowing marks a pivotal expansion in the aesthetic injectables landscape. Temple volume loss, often overlooked, contributes to a tired, aged appearance and has surged in relevance as patients experience rapid facial changes from GLP‑1‑based weight‑loss therapies. By addressing this niche, Galderma not only fills a clinical gap but also taps into a demographic eager for subtle, natural‑looking rejuvenation that complements broader facial contouring strategies.

Restylane Contour’s clinical profile underscores its market appeal. In the pivotal MA‑63365 trial, 91% of participants achieved measurable improvement at three months, and more than 85% maintained results through 18 months. Patient‑reported outcomes reveal over 70% felt younger and refreshed, while investigators rated the outcomes as natural‑looking in 99% of cases. The product’s OBT™/XpresHAn™ hyaluronic‑acid matrix integrates with skin layers, delivering flexibility and durability, and the dual‑layer, needle‑and‑cannula technique enables clinicians to tailor depth and volume with precision, reducing adverse events.

Strategically, the approval bolsters Galderma’s position amid intensifying competition from rival HA fillers. The company’s “Wake Up to Restylane” campaign leverages the new indication to promote everyday, low‑maintenance beauty, resonating with consumers seeking incremental enhancements rather than dramatic surgery. As medication‑driven weight loss expands, demand for facial volume restoration is projected to rise sharply, offering Galderma a growth engine that complements its existing cheek and mid‑face portfolio. The move also signals to investors that Galderma continues to innovate within a high‑margin, recession‑resilient segment of dermatology and aesthetic medicine.